Black cumin oil beats common asthma medications, according to new research from the journal Phytotherapy Research.
Black cumin comes from the seeds of the flowering plant Nigella Sativa, which has been revered for its medical properties for centuries. The health benefits of black cumin have been confirmed time and time again by medical research.
According to the American Academy of Allergy, Asthma, and Immunology:
The number of people with asthma continues to grow. One in 12 people (about 25 million, or 8% of the U.S. population) had asthma in 2009, compared with 1 in 14 (about 20 million, or 7%) in 2001. The new study showing that black cumin oil beats common asthma medications is great news for chronic asthma sufferers who take asthma drugs, as the FDA warned back in 2006 that certain asthma drug combinations can actually increase the risk of death from asthma.
The study was a placebo-controlled RCT performed on 80 participants with asthma, with half in the black seed group and the other half in the placebo group. The researchers noted that “Nigella sativa oil (NSO) is used traditionally for many inflammatory conditions such as asthma.” NSO was administered 500mg twice daily for 4 weeks. The placebo group received an equal dose of olive oil.
The study results were reported as follows:
“Compared with placebo, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by -50 (-155 to -1) versus 15 (-60 to 87) cells/μL (p = 0.013). NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (-1.25 to 8.75) versus 1 (-2 to 5) but non-significant (p = 0.170).” [emphasis added]
The researchers concluded: “This randomized, double-blind, placebo-controlled trial demonstrated that NSO supplementation improves asthma control with a trend in pulmonary function improvement. This was associated with a remarkable normalization of blood eosinophlia. Future studies should follow asthmatics for longer periods in a multicentre trial.”
Read original article here